Quadripling influenza virus lysatis vaccine approved for market in China

yesterday, the State Drug Administration issued a message: four-price influenza virus cracking vaccine in China was approved for marketsources said there had been a marked increase in influenza outbreaks across the country between December 2017 and early 2018To this end, the StateDrug(the Supervisory Administration, in conjunction with the relevant departments, to actively guideenterprises to(accelerate the development process of quad-price influenza vaccine, promote the vaccine to market as soon as possibleOn June 8, the State Drug Administration approved the application for registration of the production of the four-price influenza virus lysis vaccine by Hualan BiovaccineCompany(and Changchun Changsheng Biotech Co., Ltd.)it is understood that this is China's first approved four-price influenza vaccine, before the market in China's influenza vaccine is a triple-price influenza vaccineIn addition to the A1, A3 and BV viruses containing the common triamcinal influenza vaccine, the approved quadratic influenza virus is also the main strain of influenza virus in China during the 2017-2018 flu seasonthe vaccine is made by using a popular strain recommended by the World Health Organization, cultured and harvested by chicken embryos, combined with inactivated vaccine production processes, to prevent influenza virus infection in people 3 years and olderthe listing of thefour-valent influenza virus cracking vaccine is a powerful complement to the influenza virus vaccine variety in China, and it will play an important role in the prevention and control of seasonal influenza epidemic in China together with the triamcinal influenza vaccine